MICHAEL JONES: Open Payments
NPI 1407881881 · BRYAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,338 in 118 payments from 23 companies in 2025. Trend: 2023 $2,813 · 2024 $2,740 · 2025 $2,338
Food & beverage: $2,338
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 30 | $682 |
| AstraZeneca Pharmaceuticals LP | 14 | $306 |
| Lundbeck LLC | 7 | $163 |
| Amgen Inc. | 21 | $149 |
| Gilead Sciences, Inc. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $107 |
| Axsome Therapeutics, Inc. | 4 | $106 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $92 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $89 |
| Exact Sciences Corporation | 4 | $68 |
Products named: Ozempic, Wegovy, REXULTI, Rybelsus, OTEZLA, AIRSUPRA, CAPLYTA, Auvelity.
Industry payments across TX — which companies pay providers there.
